V
Vertex Pharmaceuticals
Biotech & Life Sciences · Boston, United States · Founded 1989 · IPO 1991
Focused on the discovery and development of small molecule drugs for the treatment of serious diseases MoreLess
Vertex Pharmaceuticals, accessible via vrtx.com, is a global biotechnology company dedicated to developing transformative medicines for serious diseases. The company focuses on scientific innovation and takes calculated risks to address unmet medical needs. Vertex primarily serves patients with severe and life-threatening conditions, such as cystic fibrosis, by creating groundbreaking treatments that can significantly improve their quality of life.
Operating in the biotechnology and pharmaceutical market, Vertex's business model revolves around extensive research and development (R&D) to discover and develop new drugs. The company invests heavily in scientific research, often collaborating with other biotech firms, like Arbor Biotechnologies, to advance its therapeutic pipeline. For instance, Vertex and Arbor Biotechnologies have partnered to develop novel ex vivo engineered cell therapies, which involve modifying cells outside the body to treat diseases.
Vertex generates revenue through the commercialization of its approved drugs. One of its key products is ivacaftor, a medication for cystic fibrosis, which has shown promising results in Phase 3 clinical trials. The company also earns income from licensing agreements and partnerships with other biotech firms, which help to expand its research capabilities and product offerings.
The company is led by a team of experienced executives, including Stuart A. Arbuckle, the newly appointed Chief Operating Officer. Vertex's headquarters are located in Boston, Massachusetts, but it operates on a global scale, reflecting its commitment to addressing serious health issues worldwide.
In summary, Vertex Pharmaceuticals is a pioneering biotech firm that focuses on developing innovative treatments for severe diseases, primarily through rigorous R&D and strategic partnerships. Its business model is centered on bringing new, effective drugs to market, thereby generating revenue and improving patient outcomes.
Keywords: biotechnology, pharmaceuticals, cystic fibrosis, ivacaftor, R&D, cell therapies, innovation, partnerships, serious diseases, global.
Company overview
Vertex Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 1989
- Headquarters
- Boston, United States
- Employees
- 6,448
- Open positions
- 185
- Dealroom signal
- 82.3
- Investment activity
- 10 companies · latest Jul 2026
- Capital deployed
- $396M
- Preferred round
- SERIES B
Valuation & funding
Vertex Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Jun 2026 | $0 | — | Wealthfront | ↗ |
| POST IPO EQUITY✓Other financing | Dec 2025 | $0 | — | GF Fund Management | ↗ |
| POST IPO EQUITY✓Other financing | Dec 2009 | $443M | — | Morgan Stanley · BofA Securities · Goldman Sachs | — |
| POST IPO EQUITY✓Other financing | Sep 2009 | $35M | — | Johnson & Johnson Innovative Medicine | — |
| POST IPO DEBT✓Debt | Sep 2009 | $120M | — | Undisclosed | — |
| LATE VC✓Equity / VC | Mar 2009 | Undisclosed | — | ||
| IPO✓Exit | Aug 1991 | Undisclosed | — | ||
| LATE VCEquity / VC | Jul 1989 | Norwest Venture Partners · NEA · J.H. Whitney & Co | — | ||
| EARLY VCEquity / VC | Jan 1989 | NEA · Greylock Partners · Glynn Capital Management · Avalon Ventures | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Vertex Pharmaceuticals website traffic
Latest recorded traffic for Vertex Pharmaceuticals is 200K monthly website visits, up 81.8% over the last three months. Vertex Pharmaceuticals's team grew 39.1% over the past year.
Hiring
Open positions at Vertex Pharmaceuticals
Current openings linked to this company in Dealroom.
Comparisons
Vertex Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Vertex Pharmaceuticals investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Crinetics PharmaceuticalsSan Diego, United StatesNovel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers
$7.8Bvaluation
Arbor BiotechnologiesCambridge, United StatesDiverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability
$1.1Bvaluation
Alpine Immune SciencesSeattle, United StatesImmunotherapy startup focused on developing recombinant, protein-based therapeutic solutions
$4.5Bvaluation
Entrada TherapeuticsBoston, United StatesAims to treat devastating diseases through the intracellular delivery of biologics
$109Mvaluation
ViaCyteSan Diego, United StatesFirst in Kind Cellular Treatment for Diabetes
$320Mvaluation
Semma TherapeuticsCambridge, United StatesNew class of regenerative medicine therapies couples its breakthrough stem cell technologies with proprietary delivery systems designed to protect cells from the immune system
$950Mvaluation
GenomicsOxford, United KingdomUnited kingdom-based genomic data company
$185Mvaluation
CRISPR TherapeuticsSwitzerlandGene-based medicines for patients with serious diseases
$4.2Bvaluation
Talent graph
Vertex Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Vertex Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about Vertex Pharmaceuticals
Recent press, funding announcements, and product moves mentioning Vertex Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Vertex Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Vertex Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vertex Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.